Greenwich LifeSciences, Inc.
NCM: GLSILive Quote
📈 ZcoreAI Score
Our AI model analyzes Greenwich LifeSciences, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get GLSI Z-Score →About Greenwich LifeSciences, Inc.
Healthcare
Biotechnology
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
📊 Fundamental Analysis
Greenwich LifeSciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -543.4%, which indicates that capital utilization is currently under pressure.
At a current price of $25.78, GLSI currently sits at the 68th percentile of its 52-week range (Range: $7.78 - $34.10).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$357.17M
Trailing P/E
--
Forward P/E
-31.44
Beta (5Y)
1.53
52W High
$34.10
52W Low
$7.78
Avg Volume
335K
Day High
Day Low